Marinomed Biotech AG

Equities

MARI

ATMARINOMED6

Pharmaceuticals

Market Closed - Wiener Boerse 11:35:20 2024-04-25 am EDT 5-day change 1st Jan Change
18 EUR -2.44% Intraday chart for Marinomed Biotech AG -10.00% -38.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio MT
Marinomed Biotech Signs Deal With DKSH to Commercialize Carragelose in Four Countries MT
Transcript : Marinomed Biotech AG, Nine Months 2023 Earnings Call, Nov 21, 2023
Marinomed Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Marinomed Biotech AG, H1 2023 Earnings Call, Aug 17, 2023
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Marinomed Biotech Enters Technical Cooperation with Chinese Pharmaceutical Group MT
Austria’s Marinomed Biotech Secures Mexican Market Authorization for Nasal Spray MT
Marinomed Biotech AG Announces Changes to Its Board CI
Transcript : Marinomed Biotech AG, Q1 2023 Earnings Call, May 23, 2023
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Marinomed Biotech AG, 2022 Earnings Call, Apr 19, 2023
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Austria's Marinomed Biotech Secures US Patent for Solubilization Technology MT
Marinomed Biotech AG Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022 CI
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Marinomed Biotech AG Announces Management Appointments CI
Transcript : Marinomed Biotech AG, Q1 2022 Earnings Call, May 23, 2022
Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022 CI
Marinomed Biotech AG Enters into License Agreement with Proc & Gamble on Carragelose Products CI
Transcript : Marinomed Biotech AG, 2021 Earnings Call, Apr 13, 2022
Chart Marinomed Biotech AG
More charts
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
18.45 EUR
Average target price
63 EUR
Spread / Average Target
+241.46%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. MARI Stock
  4. News Marinomed Biotech AG
  5. Austria's Marinomed Biotech Secures US Patent for Solubilization Technology